SALT LAKE CITY, Utah — September 22, 2026
SALT LAKE CITY, Utah — September 22, 2026 — Seek Labs announced the Open Impact Sequence Ablation Therapeutics Program, a three-year Commitment to Action through the Clinton Global Initiative focused on advancing therapeutic development for neglected and underserved infectious diseases. The program will initially select two diseases from a portfolio of 11 targets, including Rift Valley fever, chikungunya, Japanese encephalitis, hepatitis E, Zika, vaccine-derived polio and rabies. Seek Labs will contribute its BioSeeker genomic intelligence, therapeutic designs and technical instructions without an upfront licensing barrier, while external research institutions and disease experts will support candidate validation and development.
BioSeeker AI Maps Disease Vulnerabilities
Seek Labs’ BioSeeker platform uses AI-powered genomic analysis to identify disease vulnerabilities and sequence-defined targets that can inform therapeutic development. The company says BioSeeker has mapped 145 infectious diseases representing approximately 95% of the global infectious-disease burden, creating a genomic intelligence foundation for identifying conserved vulnerabilities and disease-driving genetic dependencies. The platform is being applied across infectious diseases and oncology, with programs including influenza, RSV, dengue, Ebola and Ewing sa
Sequence Ablation Therapeutics Enable Programmable Desi
Sequence Ablation Therapeutics (SAT) are investigational programmable therapeutics designed to act directly on disease-driving genetic sequences identified through BioSeeker. Under the Open Impact model, Seek Labs will provide target intelligence, SAT therapeutic designs, specificity analysis and technical instructions, while external partners conduct laboratory validation and return structured experimental data. The iterative approach is intended to enable candidate selection and refinement while creating a development framework that could potentially be replicated across diseases receiving limited commercial investment
Seek Labs Builds Collaborative Global Disease Model
The Open Impact program brings together technology, research institutions and mission-aligned organizations to address diseases spanning human health, maternal and child health, outbreak preparedness, veterinary medicine and food security. Seek Labs is seeking participation from research institutions, disease experts, governments, philanthropic organizations and other partners to advance the initial programs and potentially expand the model to additional diseases and regions. SAT candidates remain investigational and have not been approved for human or veterinary use by the FDA, USDA or other regulatory authorities, unless expressly stated.
Source :Seek Labs press release



